We scan new podcasts and send you the top 5 insights daily.
Matias says many hot biotech companies use AI without being AI-first; the harder problem is delivery. For RNA and oligo therapies, he highlights crossing the blood-brain barrier with brain shuttles and getting compounds inside the right cell. Those enabling technologies are where SciMed is seeing interesting companies.
The biggest obstacle holding back the entire RNA field, including mRNA and oligonucleotides, is the challenge of delivering these therapies beyond the liver. A breakthrough in novel delivery mechanisms is considered more critical for unlocking the modality's therapeutic potential than discovering new RNA molecules.
Recognizing that severe myotonic dystrophy involves CNS impairment, Arthex deliberately invested in a lipid conjugation delivery system for its RNA therapeutic. This strategic choice was made specifically to cross the blood-brain barrier, enabling the treatment of both muscular and neurological symptoms of the disease.
The next breakthrough in RNA therapeutics won't come from a single innovation. It requires combining two key elements: a 'programmable' mRNA payload designed to be active only in specific cells, and a targeted delivery system to get it there. This two-part solution represents the next generation of in-vivo therapies.
The historical difficulty of delivering biologics to the brain is being addressed by novel "brain shuttle" technologies. These platforms, which facilitate transport across the blood-brain barrier, are enabling new enzyme replacement therapies and even AAV-delivered biologics for CNS diseases like leukodystrophies.
While current RNAi therapies are successful, they almost exclusively target liver cells (hepatocytes). The industry is only at the beginning of its journey. The real, massive opportunity lies in cracking the delivery challenge to target other cells, tissues, and organs with unmet medical needs.
Bio Arctic's "brain transporter" technology is differentiated from competitors. By carefully selecting where its antibody binds on the transferrin receptor, it avoids impacting red blood cells (reticulocytes). This preclinical finding suggests a better safety profile, a key competitive advantage that likely attracts major pharma partners.
While AI for novel drug discovery has lofty goals, its most practical value lies in accelerating development. This includes applying AI to de-risked assets for new indications, improving delivery methods, and designing faster, more effective clinical trials, which is where the real bottleneck lies.
Arrowhead's demonstration of over 80% tau knockdown in CSF signals that transferrin-mediated delivery is expanding beyond enzymes and antibodies into siRNA conjugates. Much like GalNAc revolutionized liver targeting, transferrin technology is maturing across multiple competitors to overcome blood-brain barrier penetration challenges.
CNS therapeutic delivery is a multi-layered hierarchy rather than just crossing the blood-brain barrier. Effective delivery requires achieving adequate exposure in specific anatomical brain regions, verifying target engagement within precise cell types, and achieving proper intracellular trafficking for advanced modalities like ASOs, siRNAs, and AAVs.
While leveraging its current liver-focused platform for scalability, Prime Medicine's CEO identifies drug delivery as the key to unlocking future growth. The company is actively scouting for breakthroughs that will allow them to apply their prime editing technology to complex tissues like the brain, muscle, and heart, signaling a critical industry-wide bottleneck.